Eight biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Heron Therapeutics Inc (HRTX) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. In Portfolio Grader’s specific subcategory of Earnings Momentum, HRTX also gets an A. For more information, get Portfolio Grader’s complete analysis of HRTX stock.
This week, Acorda Therapeutics, Inc. (ACOR) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
This is a strong week for MediciNova, Inc. (MNOV). The company’s rating climbs to A from the previous week’s B. Medicinova acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.
Cytokinetics, Incorporated (CYTK) improves from a C to a B rating this week. Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of CYTK stock.
This week, Aurinia Pharmaceuticals Inc. (AUPH) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of AUPH stock.
Regeneron Pharmaceuticals, Inc. (REGN) earns an A this week, jumping up from last week’s grade of B. Regeneron Pharmaceuticals researches, develops and commercializes therapeutics to treat human disorders and conditions. For more information, get Portfolio Grader’s complete analysis of REGN stock.
Ambit Biosciences Corp. (AMBI) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of AMBI stock.
The rating of Cepheid (CPHD) moves up this week, rising from a C to a B. Cepheid is a molecular diagnostics company that engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. For more information, get Portfolio Grader’s complete analysis of CPHD stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
